Is Tykerb GSK's cancer breakthrough?

You win some, you lose some. While the FDA was dashing cold water on GlaxoSmithKline's HPV vaccine, breast cancer researchers were revealing studies that may drive Tykerb sales upward. Presented at the San Antonio Breast Cancer Symposium, one new trial showed that Tykerb cut breast cancer stem cells, helping to eradicate the disease in some patients. Another study showed that using Tykerb as part of a drug cocktail shrank metastatic brain tumors by at least 20 percent.

Meanwhile, European regulators gave the drug a conditional thumbs-up. The FDA approved Tykerb for use against advanced breast cancer last spring. Right now, the $47 billion cancer market is dominated by Roche and Genentech. If Glaxo could get a firm foothold with Tykerb, it may make some inroads.

- see the release
- take a look at the the brain tumor news
- read the EMEA news
- get more from the Houston Chronicle

ALSO: Take a look at GSK's pipeline. Report

Related Articles:
GSK shakes up R&D. Report
FDA scolds GSK for hyping cancer drug. Report
Tykerb gains priority review. Report
GSK stakes claim to ASCO spotlight. Report
GSK halts cancer trial on positive data. Report

Suggested Articles

Imbruvica has enjoyed a nice run in previously untreated CLL over the last few years. But major competition is here in the form of AZ's Calquence.

Pennsylvania's Supreme Court revived thousands of lawsuits alleging the antipsychotic med Risperdal caused males to develop breasts.

In the asthma biologics race, there doesn't appear to be a clear favorite among Xolair, Dupixent, Fasenra and Nucala for a group of pulmonologists.